We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

EKF Diagnostics Celebrates Success at MEDICA 2012

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

EKF Diagnostics’ success at MEDICA 2012 has been highlighted by a list of impressive statistics. The worldwide manufacturer of point-of-care (POC) diagnostic tools attracted numerous visitors to find out more about the 10 key products displayed on its 100m2 stand.  Generating the greatest interest was the European launch of two new POC products: the Quo-Lab glycated haemoglobin (HbA1c) analyser for the affordable management of diabetes; and the STAT-SiteTM M ßHB strip-based analyser, for highly accurate near patient testing of ketosis.

Over 200 product demos and 66 customer meetings were given to delegates to demonstrate the qualities of EKF Diagnostics’ newest POC solutions. The semi-automated, CE marked Quo-Lab analyser monitors HbA1c, which is increasingly used in the detection and management of diabetes, and provides a highly accurate, affordable and easy-to-use technology for GP surgeries, diabetes clinics and laboratories. The STAT-SiteTM M ßHB has been developed for the measurement of ß-Hydroxybutyrate (ßHB), the main ketone produced during ketosis, and provides a quantitative and accurate assessment of patients displaying symptoms of ketosis. This makes ketosis testing easier and more affordable in POC settings.

Nine free mini-seminars, attended by 121 delegates, outlined the benefits of using Quo-Lab and STAT SiteTM M ßHB, alongside the Lactate Scout+ for lactate measurement in obstetrics, and the Hemo-Control Manager for haemoglobin analysis and data management. A range of clinical chemistry reagents were also presented by EKF product specialists, including the ß-Hydroxybutyrate (ßHB) LiquiColor® Reagent System developed by EKF subsidiary, Stanbio Laboratory, which is relied on by 13 of the USA’s top 25 diabetes and endocrinology hospitals for its rapid and reliable results.

According to Julian Baines, Group CEO, “The launch of our two new POC products for diabetes and ketosis testing at Medica this year was a tremendous success, which was reflected in the interest shown by the large number of attendees visiting our stand. We were delighted with the response to our seminar series. The seminars provided a great way to update customers Quo-Lab and STAT-Site M BHB and also brush up their knowledge on established EKF products.”